| Literature DB >> 31515729 |
Peipei Jiang1, Xiaoqiu Tang1, Huiyan Wang1, Chenyan Dai1, Jing Su1, Hui Zhu1, Minmin Song1, Jingyu Liu2, Ziqing Nan3, Tong Ru1, Yaling Li1, Jingmei Wang4, Jun Yang4, Bing Chen5, Jianwu Dai6, Yali Hu7.
Abstract
Intrauterine adhesion (IUA) is a common cause of uterine infertility and one of the most severe clinical features is endometrial fibrosis namely endometrial scarring for which there are few cures currently. Blocked angiogenesis is the main pathological change in the scarred endometrium. The fibroblast growth factor 2 (bFGF), a member of FGF family, is usually applied to promote healing of refractory ulcer and contributes to angiogenesis of tissues. In this study, the sustained-release system of bFGF 100 µg was administrated around scarred endometrium guiding by ultrasound every 4 weeks in 18 patients (2-4 times). Results showed that after treatment, the menstrual blood volume, endometrial thickness and the scarred endometrial area were improved. Histological study showed blood vessel density increased obviously. Three patients (3/18) achieved pregnancy over 20 gestational weeks. Therefore, administrating the bFGF surrounding scarred endometrium may provide a new therapeutic approach for the patients with endometrial fibrosis.Entities:
Keywords: CBD-bFGF; endometrial reconstruction; endometrial scarring; intrauterine adhesion; thin endometrium; uterine infertility
Mesh:
Substances:
Year: 2019 PMID: 31515729 DOI: 10.1007/s11427-018-9520-2
Source DB: PubMed Journal: Sci China Life Sci ISSN: 1674-7305 Impact factor: 6.038